128 related articles for article (PubMed ID: 20306451)
1. Assessment of biomarkers for clinical diagnosis of papillary thyroid carcinoma with distant metastasis.
Liang H; Zhong Y; Luo Z; Huang Y; Lin H; Luo M; Zhan S; Xie K; Ma Y; Li QQ
Int J Biol Markers; 2010; 25(1):38-45. PubMed ID: 20306451
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of 16 cellular tumor markers for metastatic thyroid cancer: an immunohistochemical study.
Liang H; Zhong Y; Luo Z; Huang Y; Lin H; Zhan S; Xie K; Li QQ
Anticancer Res; 2011 Oct; 31(10):3433-40. PubMed ID: 21965758
[TBL] [Abstract][Full Text] [Related]
3. Coexpressed High Levels of VEGF-C and Active MMP-9 Are Associated With Lymphatic Spreading and Local Invasiveness of Papillary Thyroid Carcinoma.
Šelemetjev S; Ðoric I; Paunovic I; Tatic S; Cvejic D
Am J Clin Pathol; 2016 Nov; 146(5):594-602. PubMed ID: 27806941
[TBL] [Abstract][Full Text] [Related]
4. [Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid].
Wang T; Jiang CX; Li Y; Liu X
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):824-8. PubMed ID: 20193458
[TBL] [Abstract][Full Text] [Related]
5. Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway.
Kim DS; Franklyn JA; Boelaert K; Eggo MC; Watkinson JC; McCabe CJ
J Clin Endocrinol Metab; 2006 Nov; 91(11):4603-11. PubMed ID: 16926250
[TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of expression of VEGF and bFGF in thyroid carcinoma].
Tian XF; Zhang XW; Chen RX; Wang JW; Zhang D
Zhonghua Wai Ke Za Zhi; 2004 Jul; 42(14):864-6. PubMed ID: 15363277
[TBL] [Abstract][Full Text] [Related]
7. Co-regulatory potential of vascular endothelial growth factor-A and vascular endothelial growth factor-C in thyroid carcinoma.
Salajegheh A; Pakneshan S; Rahman A; Dolan-Evans E; Zhang S; Kwong E; Gopalan V; Lo CY; Smith RA; Lam AK
Hum Pathol; 2013 Oct; 44(10):2204-12. PubMed ID: 23845470
[TBL] [Abstract][Full Text] [Related]
8. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas.
Maeta H; Ohgi S; Terada T
Virchows Arch; 2001 Feb; 438(2):121-8. PubMed ID: 11253113
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical levels of cyclo-oxygenase-2, matrix metalloproteinase-9 and vascular endothelial growth factor in papillary thyroid carcinoma and their clinicopathological correlations.
Meng XY; Zhang Q; Li Q; Lin S; Li J
J Int Med Res; 2014 Jun; 42(3):619-27. PubMed ID: 24670538
[TBL] [Abstract][Full Text] [Related]
10. Expression of cell-cycle regulators (cyclin D1, cyclin E, p27kip1, p57kip2) in papillary thyroid carcinoma.
Lee SH; Lee JK; Jin SM; Lee KC; Sohn JH; Chae SW; Kim DH
Otolaryngol Head Neck Surg; 2010 Mar; 142(3):332-7. PubMed ID: 20172376
[TBL] [Abstract][Full Text] [Related]
11. Expression of matrix metalloproteinase-2 and its tissue inhibitor-2 in fetal and neoplastic thyroid tissue and their significance as diagnostic and prognostic markers in papillary carcinoma.
Marečko I; Cvejić D; Tatić S; Dragutinović V; Paunović I; Savin S
Cancer Biomark; 2011-2012; 11(1):49-58. PubMed ID: 22820140
[TBL] [Abstract][Full Text] [Related]
12. [Expression and significance of VEGF, VEGF-C, and VEGF-D in papillary thyroid carcinoma].
Jiang HG; Gao M; Tang WP; Li FH; Cai QZ
Ai Zheng; 2005 Sep; 24(9):1136-9. PubMed ID: 16159441
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients.
Siironen P; Louhimo J; Nordling S; Ristimäki A; Mäenpää H; Haapiainen R; Haglund C
Tumour Biol; 2005; 26(2):57-64. PubMed ID: 15870511
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis based Ep-ICD subcellular localization index (ESLI) is a novel marker for metastatic papillary thyroid microcarcinoma.
Kunavisarut T; Kak I; Macmillan C; Ralhan R; Walfish PG
BMC Cancer; 2012 Nov; 12():523. PubMed ID: 23153310
[TBL] [Abstract][Full Text] [Related]
15. Deciphering novel biomarkers of lymph node metastasis of thyroid papillary microcarcinoma using proteomic analysis of ultrasound-guided fine-needle aspiration biopsy samples.
Lin P; Yao Z; Sun Y; Li W; Liu Y; Liang K; Liu Y; Qin J; Hou X; Chen L
J Proteomics; 2019 Jul; 204():103414. PubMed ID: 31195151
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter.
Inoue K; Kamada M; Slaton JW; Fukata S; Yoshikawa C; Tamboli P; Dinney CP; Shuin T
Clin Cancer Res; 2002 Jun; 8(6):1863-70. PubMed ID: 12060629
[TBL] [Abstract][Full Text] [Related]
17. Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas.
Kilicarslan AB; Ogus M; Arici C; Pestereli HE; Cakir M; Karpuzoglu G
APMIS; 2003 Mar; 111(3):439-43. PubMed ID: 12752224
[TBL] [Abstract][Full Text] [Related]
18. Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer.
Lin SY; Wang YY; Sheu WH
Clin Endocrinol (Oxf); 2003 Apr; 58(4):513-8. PubMed ID: 12641636
[TBL] [Abstract][Full Text] [Related]
19. Relationship between protein expression of VEGF-C, MMP-2 and lymph node metastasis in papillary thyroid cancer.
Tian X; Cong M; Zhou W; Zhu J; Liu Q
J Int Med Res; 2008; 36(4):699-703. PubMed ID: 18652765
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of protein expression in differentiated thyroid tumours: a multicentre study.
Liang HS; Zhong YH; Luo ZJ; Huang Y; Lin HD; Luo M; ; Su HX; Zhou SB; Xie KQ
J Int Med Res; 2009; 37(3):927-38. PubMed ID: 19589279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
